# Nutanix, Inc.: financial statements, quarterly

NTNX · Nasdaq · CIK 1618732 · [Technology](/sectors/technology.md) · fiscal year ends Jul 31

Pages: [Overview](/companies/ntnx.md) · [Financials](/companies/ntnx/financials.md) · [Filings](/companies/ntnx/filings.md) · [Insiders](/companies/ntnx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ntnx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2024 (2023-10-31) | Q2 FY2024 (2024-01-31) | Q3 FY2024 (2024-04-30) | Q4 FY2024 (2024-07-31) | Q1 FY2025 (2024-10-31) | Q2 FY2025 (2025-01-31) | Q3 FY2025 (2025-04-30) | Q4 FY2025 (2025-07-31) | Q1 FY2026 (2025-10-31) | Q2 FY2026 (2026-01-31) | Q3 FY2026 (2026-04-30) | Q4 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [511](/filings/0000950170-24-133675.md) | [565](/filings/0000950170-25-034610.md) | [525](/filings/0000950170-25-080917.md) | [548 d](/filings/0001193125-26-394793.md) | [591](/filings/0001193125-25-308095.md) | [655](/filings/0001193125-26-085397.md) | [639](/filings/0001193125-26-248282.md) | [653 d](/filings/0001193125-26-394793.md) | [671](/filings/0001193125-25-308095.md) | [723](/filings/0001193125-26-085397.md) | [703](/filings/0001193125-26-248282.md) | [757 d](/filings/0001193125-26-394793.md) |
| Cost of revenue | $m | [82.0](/filings/0000950170-24-133675.md) | [81.6](/filings/0000950170-25-034610.md) | [79.6](/filings/0000950170-25-080917.md) | [81.0 d](/filings/0001193125-26-394793.md) | [82.7](/filings/0001193125-25-308095.md) | [85.3](/filings/0001193125-26-085397.md) | [83.0](/filings/0001193125-26-248282.md) | [83.8 d](/filings/0001193125-26-394793.md) | [87.5](/filings/0001193125-25-308095.md) | [91.3](/filings/0001193125-26-085397.md) | [92.3](/filings/0001193125-26-248282.md) | [106 d](/filings/0001193125-26-394793.md) |
| Gross profit | $m | [429](/filings/0000950170-24-133675.md) | [484](/filings/0000950170-25-034610.md) | [445](/filings/0000950170-25-080917.md) | [467 d](/filings/0001193125-26-394793.md) | [508](/filings/0001193125-25-308095.md) | [569](/filings/0001193125-26-085397.md) | [556](/filings/0001193125-26-248282.md) | [569 d](/filings/0001193125-26-394793.md) | [583](/filings/0001193125-25-308095.md) | [632](/filings/0001193125-26-085397.md) | [611](/filings/0001193125-26-248282.md) | [651 d](/filings/0001193125-26-394793.md) |
| Research and development | $m | [152](/filings/0000950170-24-133675.md) | [160](/filings/0000950170-25-034610.md) | [159](/filings/0000950170-25-080917.md) | [167 d](/filings/0001193125-26-394793.md) | [174](/filings/0001193125-25-308095.md) | [183](/filings/0001193125-26-085397.md) | [186](/filings/0001193125-26-248282.md) | [194 d](/filings/0001193125-26-394793.md) | [187](/filings/0001193125-25-308095.md) | [202](/filings/0001193125-26-085397.md) | [196](/filings/0001193125-26-248282.md) | [205 d](/filings/0001193125-26-394793.md) |
| Operating income | $m | [(5.7)](/filings/0000950170-24-133675.md) | [37.0](/filings/0000950170-25-034610.md) | [(11.6)](/filings/0000950170-25-080917.md) | [(12.2) d](/filings/0001193125-26-394793.md) | [27.3](/filings/0001193125-25-308095.md) | [65.4](/filings/0001193125-26-085397.md) | [48.6](/filings/0001193125-26-248282.md) | [31.2 d](/filings/0001193125-26-394793.md) | [49.3](/filings/0001193125-25-308095.md) | [84.1](/filings/0001193125-26-085397.md) | [70.5](/filings/0001193125-26-248282.md) | [70.0 d](/filings/0001193125-26-394793.md) |
| Income tax | $m | [4.9](/filings/0000950170-24-133675.md) | [6.3](/filings/0000950170-25-034610.md) | [4.7](/filings/0000950170-25-080917.md) | [7.6 d](/filings/0001193125-26-394793.md) | [6.9](/filings/0001193125-25-308095.md) | [8.7](/filings/0001193125-26-085397.md) | [1.2](/filings/0001193125-26-248282.md) | [6.5 d](/filings/0001193125-26-394793.md) | [3.5](/filings/0001193125-25-308095.md) | [(5.5)](/filings/0001193125-26-085397.md) | [9.2](/filings/0001193125-26-248282.md) | [(1,187) d](/filings/0001193125-26-394793.md) |
| Net income | $m | [(15.9)](/filings/0000950170-25-080917.md) | [32.8](/filings/0000950170-25-080917.md) | [(15.6)](/filings/0000950170-25-080917.md) | [(126) d](/filings/0001193125-26-394793.md) | [29.9](/filings/0001193125-26-248282.md) | [56.4](/filings/0001193125-26-248282.md) | [63.4](/filings/0001193125-26-248282.md) | [38.7 d](/filings/0001193125-26-394793.md) | [62.1](/filings/0001193125-26-248282.md) | [103](/filings/0001193125-26-248282.md) | [72.1](/filings/0001193125-26-248282.md) | [1,270 d](/filings/0001193125-26-394793.md) |
| Diluted EPS | $ per share | [(0.07)](/filings/0000950170-24-133675.md) | [0.12](/filings/0000950170-25-034610.md) | [(0.06)](/filings/0000950170-25-080917.md) | not reported | [0.10](/filings/0001193125-25-308095.md) | [0.19](/filings/0001193125-26-085397.md) | [0.22](/filings/0001193125-26-248282.md) | not reported | [0.21](/filings/0001193125-25-308095.md) | [0.36](/filings/0001193125-26-085397.md) | [0.25](/filings/0001193125-26-248282.md) | not reported |
| Basic EPS | $ per share | [(0.07)](/filings/0000950170-24-133675.md) | [0.13](/filings/0000950170-25-034610.md) | [(0.06)](/filings/0000950170-25-080917.md) | not reported | [0.11](/filings/0001193125-25-308095.md) | [0.21](/filings/0001193125-26-085397.md) | [0.24](/filings/0001193125-26-248282.md) | not reported | [0.23](/filings/0001193125-25-308095.md) | [0.38](/filings/0001193125-26-085397.md) | [0.27](/filings/0001193125-26-248282.md) | not reported |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2024 (2023-10-31) | Q2 FY2024 (2024-01-31) | Q3 FY2024 (2024-04-30) | FY2024 (2024-07-31) | Q1 FY2025 (2024-10-31) | Q2 FY2025 (2025-01-31) | Q3 FY2025 (2025-04-30) | FY2025 (2025-07-31) | Q1 FY2026 (2025-10-31) | Q2 FY2026 (2026-01-31) | Q3 FY2026 (2026-04-30) | FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [612](/filings/0000950170-24-133675.md) | [679](/filings/0000950170-25-034610.md) | [598](/filings/0000950170-25-080917.md) | [655](/filings/0001193125-26-394793.md) | [717](/filings/0001193125-25-308095.md) | [1,072](/filings/0001193125-26-085397.md) | [873](/filings/0001193125-26-248282.md) | [770](/filings/0001193125-26-394793.md) | [780](/filings/0001193125-25-308095.md) | [603](/filings/0001193125-26-085397.md) | [719](/filings/0001193125-26-248282.md) | [777](/filings/0001193125-26-394793.md) |
| Current assets | $m | [1,918](/filings/0000950170-23-068799.md) | [2,080](/filings/0000950170-24-027936.md) | [2,139](/filings/0000950170-24-071318.md) | [1,481](/filings/0001193125-25-213801.md) | [1,523](/filings/0000950170-24-133675.md) | [2,335](/filings/0000950170-25-034610.md) | [2,411](/filings/0000950170-25-080917.md) | [2,589](/filings/0001193125-26-394793.md) | [2,639](/filings/0001193125-25-308095.md) | [2,466](/filings/0001193125-26-085397.md) | [2,612](/filings/0001193125-26-248282.md) | [3,029](/filings/0001193125-26-394793.md) |
| Total assets | $m | [2,571](/filings/0000950170-23-068799.md) | [2,730](/filings/0000950170-24-027936.md) | [2,775](/filings/0000950170-24-071318.md) | [2,144](/filings/0001193125-25-213801.md) | [2,181](/filings/0000950170-24-133675.md) | [2,989](/filings/0000950170-25-034610.md) | [3,097](/filings/0000950170-25-080917.md) | [3,283](/filings/0001193125-26-394793.md) | [3,324](/filings/0001193125-25-308095.md) | [3,277](/filings/0001193125-26-085397.md) | [3,419](/filings/0001193125-26-248282.md) | [5,074](/filings/0001193125-26-394793.md) |
| Current liabilities | $m | [1,100](/filings/0000950170-23-068799.md) | [1,163](/filings/0000950170-24-027936.md) | [1,184](/filings/0000950170-24-071318.md) | [1,244](/filings/0001193125-25-213801.md) | [1,221](/filings/0000950170-24-133675.md) | [1,318](/filings/0000950170-25-034610.md) | [1,282](/filings/0000950170-25-080917.md) | [1,414](/filings/0001193125-26-394793.md) | [1,400](/filings/0001193125-25-308095.md) | [1,491](/filings/0001193125-26-085397.md) | [1,470](/filings/0001193125-26-248282.md) | [1,684](/filings/0001193125-26-394793.md) |
| Total liabilities | $m | [3,213](/filings/0000950170-23-068799.md) | [3,341](/filings/0000950170-24-027936.md) | [3,394](/filings/0000950170-24-071318.md) | [2,872](/filings/0001193125-25-213801.md) | [2,867](/filings/0000950170-24-133675.md) | [3,797](/filings/0000950170-25-034610.md) | [3,808](/filings/0000950170-25-080917.md) | [3,978](/filings/0001193125-26-394793.md) | [3,993](/filings/0001193125-25-308095.md) | [4,108](/filings/0001193125-26-085397.md) | [4,144](/filings/0001193125-26-248282.md) | [4,371](/filings/0001193125-26-394793.md) |
| Shareholders' equity | $m | [(642)](/filings/0000950170-25-080917.md) | [(612)](/filings/0000950170-25-080917.md) | [(619)](/filings/0000950170-25-080917.md) | [(728)](/filings/0001193125-26-394793.md) | [(685)](/filings/0001193125-26-248282.md) | [(808)](/filings/0001193125-26-248282.md) | [(711)](/filings/0001193125-26-248282.md) | [(695)](/filings/0001193125-26-394793.md) | [(669)](/filings/0001193125-26-248282.md) | [(831)](/filings/0001193125-26-248282.md) | [(726)](/filings/0001193125-26-248282.md) | [703](/filings/0001193125-26-394793.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2024 (2023-10-31) | Q2 FY2024 (2024-01-31) | Q3 FY2024 (2024-04-30) | Q4 FY2024 (2024-07-31) | Q1 FY2025 (2024-10-31) | Q2 FY2025 (2025-01-31) | Q3 FY2025 (2025-04-30) | Q4 FY2025 (2025-07-31) | Q1 FY2026 (2025-10-31) | Q2 FY2026 (2026-01-31) | Q3 FY2026 (2026-04-30) | Q4 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [145](/filings/0000950170-24-133675.md) | [186 d](/filings/0000950170-25-034610.md) | [96.4 d](/filings/0000950170-25-080917.md) | [245 d](/filings/0001193125-26-394793.md) | [162](/filings/0001193125-25-308095.md) | [222 d](/filings/0001193125-26-085397.md) | [219 d](/filings/0001193125-26-248282.md) | [220 d](/filings/0001193125-26-394793.md) | [197](/filings/0001193125-25-308095.md) | [197 d](/filings/0001193125-26-085397.md) | [208 d](/filings/0001193125-26-248282.md) | [315 d](/filings/0001193125-26-394793.md) |
| Capital expenditure | $m | [13.0](/filings/0000950170-24-133675.md) | [23.8 d](/filings/0000950170-25-034610.md) | [18.0 d](/filings/0000950170-25-080917.md) | [20.4 d](/filings/0001193125-26-394793.md) | [9.8](/filings/0001193125-25-308095.md) | [34.6 d](/filings/0001193125-26-085397.md) | [15.1 d](/filings/0001193125-26-248282.md) | [11.8 d](/filings/0001193125-26-394793.md) | [22.3](/filings/0001193125-25-308095.md) | [5.9 d](/filings/0001193125-26-085397.md) | [10.3 d](/filings/0001193125-26-248282.md) | [37.4 d](/filings/0001193125-26-394793.md) |
| Share repurchases | $m | [17.5](/filings/0000950170-24-133675.md) | [41.7 d](/filings/0000950170-25-034610.md) | [46.9 d](/filings/0000950170-25-080917.md) | [25.0 d](/filings/0001193125-26-394793.md) | [20.1](/filings/0001193125-25-308095.md) | [200 d](/filings/0001193125-26-085397.md) | [37.8 d](/filings/0001193125-26-248282.md) | [50.0 d](/filings/0001193125-26-394793.md) | [50.2](/filings/0001193125-25-308095.md) | [333 d](/filings/0001193125-26-085397.md) | [50.1 d](/filings/0001193125-26-248282.md) | [50.3 d](/filings/0001193125-26-394793.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2022-10-31) | Q2 FY2023 (2023-01-31) | Q3 FY2023 (2023-04-30) | Q1 FY2024 (2023-10-31) | Q2 FY2024 (2024-01-31) | Q3 FY2024 (2024-04-30) | Q1 FY2025 (2024-10-31) | Q2 FY2025 (2025-01-31) | Q3 FY2025 (2025-04-30) | Q1 FY2026 (2025-10-31) | Q2 FY2026 (2026-01-31) | Q3 FY2026 (2026-04-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [229](/filings/0000950170-23-068799.md) | [232](/filings/0000950170-24-027936.md) | [235](/filings/0000950170-24-071318.md) | [0.2](/filings/0000950170-24-133675.md) | [0.3](/filings/0000950170-25-034610.md) | [0.2](/filings/0000950170-25-080917.md) | [0.3](/filings/0001193125-25-308095.md) | [0.3](/filings/0001193125-26-085397.md) | [0.3](/filings/0001193125-26-248282.md) | [0.3](/filings/0001193125-25-308095.md) | [0.3](/filings/0001193125-26-085397.md) | [0.3](/filings/0001193125-26-248282.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 270,570,179 at 2026-08-31, from the cover of the [10-K filed 2026-09-18](/filings/0001193125-26-394793.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.